A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Anti-CD5 chimeric antigen receptor T cell therapy Yake Biotechnology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 16 Oct 2024 New trial record